Thin Film Electronics ASA – Reminder of last day of the subscription period in the Subsequent Offering
Oslo, 29 June 2020
Month: June 2020
Rybelsus® approved in Japan for the treatment of type 2 diabetes
Written by Customer Service on . Posted in Public Companies.
Bagsværd, Denmark, 29 June 2020 – Novo Nordisk today announced that the Japanese Ministry of Health, Labour and Welfare has approved Rybelsus® (oral semaglutide), the first and only oral glucagon-like peptide-1 receptor agonist (GLP-1 RA) in a tablet, for the treatment of adults with type 2 diabetes.The approval of Rybelsus® in Japan is based on results from the PIONEER clinical trial programme, which involved more than 9,500 adults with type 2 diabetes, including approximately 1,300 adults from Japan. The approved label reflects the Japanese studies, which showed that Rybelsus® 7 mg once daily was comparable to liraglutide 0.9 mg once daily and, in combination with one other oral antidiabetic treatment, Rybelsus® 7 mg once daily was comparable to dulaglutide 0.75 mg once weekly, while Rybelsus® 14 mg once daily resulted in significantly...
Finanskalender 2020/21
Written by Customer Service on . Posted in Public Companies.
MEDDELELSE NR. 193 Hermed følger offentliggørelsesdatoer for ChemoMetecs planlagte meddelelser, herunder også datoer for generalforsamlinger i 2020 og 2021:17. september 2020 – Årsrapport (2019/20)8. oktober 2020 – Ordinær generalforsamling5. november 2020 – Periodemeddelelse (1. kvartal 2020/21)5. februar 2021 – Halvårsrapport (2020/21)6. maj 2021 – Periodemeddelelse (3. kvartal 2020/21)16. september 2021 – Årsrapport (2020/21)7. oktober 2021 – Ordinær generalforsamlingEventuelle henvendelser:Om ChemoMetec A/SChemoMetec udvikler, producerer og markedsfører analyseinstrumenter til celletælling og en lang række andre målinger. ChemoMetecs analyseinstrumenter markedsføres globalt inden for blandt andet pharma, biotek og landbrug. ChemoMetec har nogle af verdens førende...
Burning Rock and CStone Pharmaceuticals reached a strategic collaboration on the co-development of companion diagnostics for pralsetinib in China
Written by Customer Service on . Posted in Public Companies.
SHANGHAI, China, June 28, 2020 (GLOBE NEWSWIRE) — On June 29, 2020, Burning Rock Biotech Limited (NASDAQ: BNR) announced a strategic partnership with CStone Pharmaceuticals (HKEX: 2616) to co-develop and commercialize companion diagnostics (CDx) for pralsetinib, an investigational treatment developed by CStone’s partner Blueprint Medicines, in China for the detection of RET alterations in cancer patients.“In an era of rapid development of precision medicines, CDx is of great significance to accurately identify the patient populations who could benefit from specific therapies. Burning Rock will continue to develop CDx-related products based on advanced next generation sequencing (NGS) technology, and work with partners to promote the clinical application of precision diagnostics and treatment, potentially bringing clinical benefits...
미국국립의료원 (NIH), 엠마우스생명과학에 독점 특허 라이센스 부여
Written by Customer Service on . Posted in Public Companies.
캘리포니아주 토랜스, June 29, 2020 (GLOBE NEWSWIRE) — 겸상적혈구질환 치료의 선두주자 엠마우스생명과학 (“엠마우스”, OTCQB: EMMA)은 2020년 06월 22일, 미국보건복지부, 국립보건원 산하, 국립암연구소에서 엠마우스생명과학의 자회사인 엠마우스메디컬에게 통지의 보충섹션에 나열된 특허출원 및 특허에서 구현된 발명을 발명을 실시하기 위한 독점 특허 라이선스를 부여할 계획이라고 통지하고 오늘 밝혔습니다. 통지는 다음의 링크에서 액세스 할 수 있습니다: https://bit.ly/3erJfZz. 일반국민들은 제안된 보조금에 대하여 2020년 07월 07일까지 의견을 표시하여야 합니다. 제안된 라이선스의 조건은 공개되지 않았습니다.이 특허기술은 국부투여를 위하여 백색와셀린, 미네랄오일 및 비사보롤에 분산되어 있는 0.5%에서 3.0% 중량의 비산성화된 아질산나트륨을 포함하는 연고제제입니다. 아질산염 음이온은 산소장력과 pH가 낮은 조직에서 산화질소를 생성함으로써 생체 내 혈관확장제의 역할을 할 수 있습니다. 이런 제형을 통한 아질산나트륨의 치료적 적용은 겸상적혈구질환 및 2 형 당뇨병을 포함하여 여러질환관 관련된 만선허혈성 및 신경병질의 궤양과 관련성이 있는 궤양을 치료하는 저산소 조직에 선택적 혈관확장을 제공할 수 있습니다.“혁신적이고 새로운 치료법을 발견하기 위해 노력하는 미국국립의료원 및 재능 있는 발명가들과 일할 수 있게 되어 매우 기쁩니다. 피부궤양은 겸상적혈구질환의 중증, 만성 및 재발성 합병증입니다. 우리는 겸상적혈구질환 및 당뇨병과 같은 다른 질병과 관련된 피부궤양을 치료하기 위하여 이런 유망한 치료법을 개발하기를 기대합니다.”라고 엠마우스의...
Toscana Energy Announces First Quarter 2020 Results
Written by Customer Service on . Posted in Earnings Releases And Operating Results.
CALGARY, Alberta, June 26, 2020 (GLOBE NEWSWIRE) — Toscana Energy Income Corporation (“Toscana” or the “Corporation”) (TSX: TEI) announces financial and operating results for the first quarter ended March 31, 2020.Financial and operating results:
Staffing 360 Solutions Reports First Quarter 2020 Results
Written by Customer Service on . Posted in Earnings Releases And Operating Results.
Pandemic-Impacted Revenue Slowly ImprovingNEW YORK, June 26, 2020 (GLOBE NEWSWIRE) — Staffing 360 Solutions, Inc. (NASDAQ: STAF), a company executing an international buy-integrate-build strategy through the acquisition of staffing organizations in the United States and the United Kingdom, today announced Fiscal 2020 first quarter results, which were impacted in March by the economic downturn resulting from the COVID-19 pandemic.Brendan Flood, Chairman and Chief Executive Officer said, “Q1 results were directly in line with the guidance provided in our year-end financial results call. As anticipated, the revenue decline was principally due to the loss of a low-margin client in the UK and the impact of IR35 payroll tax legislation in the UK. Additionally, late in the quarter both countries in which we do business were negatively...
Results of Operations for the Year Ended December 31, 2019 – American Overseas Group Limited Announces Net Loss Of $3.7 Million and Operating Loss of $9.1 Million For the Year Ended December 31, 2019
Written by Customer Service on . Posted in Earnings Releases And Operating Results.
HAMILTON, Bermuda, June 26, 2020 (GLOBE NEWSWIRE) — American Overseas Group Limited (BSX: AORE.BH) (Pink Sheets: AOREF.PK) (“AOG” or the “Company”) today reported consolidated net loss available to common shareholders of $3.7 million, or $80.13 per diluted share, for the year ended December 31, 2019. This compares to consolidated net loss available to common shareholders of $3.2 million, or $69.12 per diluted share, for the year ended December 31, 2018.The results for the year were driven by losses in the Company’s financial guaranty segment related to commuted policies and Puerto Rico related credits. Book value per share at December 31, 2019 was $1,159.08, a decline from the book value per share of $1,212.83 at December 31, 2018. For the year ended December 31, 2019, the Company had an operating loss of $9.1 million, or $196.78...
Brattle Street Investment Releases Audited Financial Statements for Year Ended February 29, 2020
Written by Customer Service on . Posted in Earnings Releases And Operating Results.
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES.NEW YORK, June 26, 2020 (GLOBE NEWSWIRE) — Brattle Street Investment Corp. (“Brattle” or the “Company”) (TSXV:BRTL), today posted its audited financial statements for the year ending February 29, 2020. At year-end, the company’s audited balance sheet had a total of $9,192,643 in liquid assets, comprised of cash ($8,349,422) and marketable securities ($843,221), which is approximately $0.20 per share.The Company continues to seek opportunities that provide attractive returns relative to risk. Before the COVID-19 pandemic, the Company began pursuing a specific transaction. The Company recently devoted significant resources towards pursing the transaction, but management ultimately terminated negotiations when the arm’s length seller was...
Knight Therapeutics Reports First Quarter 2020 Results
Written by Customer Service on . Posted in Earnings Releases And Operating Results.
MONTREAL, June 26, 2020 (GLOBE NEWSWIRE) — Knight Therapeutics Inc. (TSX: GUD) (“Knight” or “the Company”), a leading pan-American (ex-US) specialty pharmaceutical company, today reported financial results for its first quarter ended March 31, 2020. All currency amounts are in thousands except for share and per share amounts. All currencies are Canadian unless otherwise specified.Q1 2020 Highlights
